A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors

Mark W. Kieran, Susan Chi, Stewart Goldman, Arzu Onar-Thomas, Tina Young Poussaint, Sridhar Vajapeyam, Frederic Fahey, Shengjie Wu, David C. Turner, Clinton F. Stewart, Marsha Moses, Roger J. Packer, Regina Jakacki, Anu Banerjee, James M. Boyett, Maryam Fouladi, Larry Kun